Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treated
Abiomed, Inc. (NASDAQ:ABMD), a leading provider...
Read MoreAbiomed, Inc. (NASDAQ:ABMD), a leading provider...
Read MoreMutations in the gene LRRK2...
Read MoreThe Drug Technical Advisory Board...
Read MoreGlaxoSmithKline is taking a deeper...
Read MoreKarnataka falls behind six states...
Read MoreKeeping in mind the needs...
Read MoreSun Pharmaceutical Industries today said...
Read MoreBIOCRATES Life Sciences AG -...
Read MoreBiohaven Pharmaceutical (Biohaven) has initiated...
Read More